BackTable / Urology / Contributor

Dr. Eugene Pietzak

Urologic Oncologist

Dr. Eugene Pietzak is a urologic oncologist with Memoral Sloan Kettering in New York City.

Visit Dr. Eugene Pietzak's Twitter Profile

Listen to Dr. Eugene Pietzak on the BackTable Urology Podcast

The BackTable Podcast is a knowledge resource by physicians for physicians. Learn from the experiences and expertise of Dr. Eugene Pietzak and get practical advice on how to build your practice by listening to the BackTable Urology Podcast.

Ep 64 Management of BCG-refractory NMIBC with Dr. Timothy Clinton and Dr. Eugene Pietzak

00:00 / 01:04

More about this episode

Stay Up To Date

Follow:

Subscribe:

About Dr. Eugene Pietzak

Dr. Eugene Pietzak, MD, is a board-certified urologic surgeon who specializes in the surgical treatment of bladder cancer, prostate cancer, upper urothelial cancer, and other cancers of the genitourinary system. He has expertise in a wide array of surgical techniques, including minimally invasive and robotic surgery.

Dr. Pietzak received his medical degree from the State University of New York/Health Science Center at Stony Brook in 2010. He has over 14 years of experience, and is affiliated with St. Francis Hospital & Heart Center, Boca Raton Regional Hospital, New York Presbyterian Hospital, Stony Brook University Hospital, Guthrie Corning Hospital and Memorial Sloan Kettering Cancer Center.

Learn more by visiting Dr. Eugene Pietzak's practice:

Memorial Sloan Kettering Cancer Center

Podcasts Featuring Dr. Eugene Pietzak

Episode #64

Management of BCG-refractory NMIBC

In this episode of BackTable Urology, Dr. Aditya Bagrodia speaks with two fellow urologic oncologists, Dr. Timothy Clinton (Brigham and Women’s Hospital) and Dr. Eugene Pietzak (Memorial Sloan Kettering), about the management of BCG-refractory non muscle-invasive bladder cancer.

Articles Featuring Dr. Eugene Pietzak

High-Grade BCG-Unresponsive Bladder Cancer Management & Alternatives

The management of high-grade BCG-unresponsive bladder cancer begins with the establishment of cytology and, based on the patient profile, is followed by either TURBT or total cystectomy. Alternatives to BCG for bladder cancer are available, but ongoing research continues to explore other options.

Recommendations for BCG-Unresponsive Bladder Cancer

BCG-unresponsive bladder cancer has distinct criteria for diagnosis and management. Official FDA diagnosis requires the development or recurrence of a high-grade bladder tumor after a patient has received adequate BCG therapy. Treatment duration varies based on whether an induction or maintenance course is indicated.

Get Connected

Thank you for listening! If you have a question for Dr. Eugene Pietzak about a topic discussed on the BackTable Urology Podcast, you can get in touch with this form. Please note that our contributors are not able to respond to every inquiry.

Disclaimer: The Materials available on BackTable.com are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.